NASDAQ: MURA
Mural Oncology PLC Stock Forecast, Predictions & Price Target

Analyst price target for MURA

Based on 2 analysts offering 12 month price targets for Mural Oncology PLC

Min Forecast
$6.00+123.05%
Avg Forecast
$11.00+308.92%
Max Forecast
$16.00+494.8%

Should I buy or sell MURA stock?

Based on 2 analysts offering ratings for Mural Oncology PLC.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MURA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MURA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their MURA stock forecasts and price targets.

MURA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-26
lockedlocked$00.00+00.00%2025-01-27

1 of 1

Forecast return on equity

Is MURA forecast to generate an efficient return?

Company
-27.34%
Industry
153.19%
Market
81.87%
MURA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MURA forecast to generate an efficient return on assets?

Company
-22.68%
Industry
36.07%
MURA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MURA earnings per share forecast

What is MURA's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$4.79
Avg 2 year Forecast
-$2.01
Avg 3 year Forecast
-$2.19

MURA revenue forecast

What is MURA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$5.6M
Avg 2 year Forecast
$4.8M
Avg 3 year Forecast
$18.6M

MURA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MURA$2.69$11.00+308.92%Strong Buy
STRO$0.55$5.50+896.38%Hold
IPSC$0.54$4.00+640.74%Strong Buy
QNCX$1.05$8.00+661.90%Strong Buy
FBRX$7.01$61.00+770.19%Strong Buy

Mural Oncology Stock Forecast FAQ

Is Mural Oncology Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MURA) stock is to Strong Buy MURA stock.

Out of 2 analysts, 1 (50%) are recommending MURA as a Strong Buy, 1 (50%) are recommending MURA as a Buy, 0 (0%) are recommending MURA as a Hold, 0 (0%) are recommending MURA as a Sell, and 0 (0%) are recommending MURA as a Strong Sell.

If you're new to stock investing, here's how to buy Mural Oncology stock.

What is MURA's earnings growth forecast for 2025-2027?

(NASDAQ: MURA) Mural Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Mural Oncology's earnings in 2025 is -$128,514,000.On average, 3 Wall Street analysts forecast MURA's earnings for 2025 to be -$82,466,661, with the lowest MURA earnings forecast at -$97,339,844, and the highest MURA earnings forecast at -$58,231,624. On average, 3 Wall Street analysts forecast MURA's earnings for 2026 to be -$34,628,865, with the lowest MURA earnings forecast at -$57,197,926, and the highest MURA earnings forecast at -$3,273,375.

In 2027, MURA is forecast to generate -$37,729,957 in earnings, with the lowest earnings forecast at -$58,748,472 and the highest earnings forecast at -$3,101,092.

What is MURA's revenue growth forecast for 2025-2027?

(NASDAQ: MURA) Mural Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Mural Oncology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast MURA's revenue for 2025 to be $97,167,561, with the lowest MURA revenue forecast at $97,167,561, and the highest MURA revenue forecast at $97,167,561. On average, 2 Wall Street analysts forecast MURA's revenue for 2026 to be $82,178,948, with the lowest MURA revenue forecast at $67,190,335, and the highest MURA revenue forecast at $97,167,561.

In 2027, MURA is forecast to generate $320,963,061 in revenue, with the lowest revenue forecast at $249,121,088 and the highest revenue forecast at $413,478,984.

What is MURA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MURA) forecast ROA is -22.68%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is MURA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MURA price target, the average MURA price target is $11.00, with the highest MURA stock price forecast at $16.00 and the lowest MURA stock price forecast at $6.00.

On average, Wall Street analysts predict that Mural Oncology's share price could reach $11.00 by Mar 26, 2026. The average Mural Oncology stock price prediction forecasts a potential upside of 308.92% from the current MURA share price of $2.69.

What is MURA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MURA) Mural Oncology's current Earnings Per Share (EPS) is -$7.58. On average, analysts forecast that MURA's EPS will be -$4.79 for 2025, with the lowest EPS forecast at -$5.65, and the highest EPS forecast at -$3.38. On average, analysts forecast that MURA's EPS will be -$2.01 for 2026, with the lowest EPS forecast at -$3.32, and the highest EPS forecast at -$0.19. In 2027, MURA's EPS is forecast to hit -$2.19 (min: -$3.41, max: -$0.18).

What is MURA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MURA) forecast ROE is -27.34%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.